Long-term effect of sub-anesthetic ketamine in reducing L-DOPA-induced dyskinesias in a preclinical model

Documenti analoghi

• Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia
  di: Bartlett, Mitchell J., et al.
  Pubblicazione: (2020)
• Case Reports Showing a Long-Term Effect of Subanesthetic Ketamine Infusion in Reducing l-DOPA-Induced Dyskinesias
  di: Sherman, Scott J., et al.
  Pubblicazione: (2016)
• The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced L-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia
  di: Flores, Andrew J., et al.
  Pubblicazione: (2018)
• Highly-selective µ-opioid receptor antagonism does not block L-DOPA-induced dyskinesia in a rodent model
  di: Bartlett, Mitchell J., et al.
  Pubblicazione: (2020)
• The Delta-Specific Opioid Glycopeptide BBI-11008: CNS Penetration and Behavioral Analysis in a Preclinical Model of Levodopa-Induced Dyskinesia
  di: Bartlett, Mitchell J., et al.
  Pubblicazione: (2020)